The theory and principles of gene delivery for therapeutic function have been well documented. Even though viral vectors, weighed against non-viral vectors such as lipoplexes and polyplexes, are far more competent in bringing about cellular transfection, inherent immunity problem compromise their protective use in vivo. Although vulnerabilities consist of mutational insertion hazard and exposure, potentially leading to oncogenicity, large scale production of viral vectors as such might also represent an impediment. Though less efficient, particularly in vivo, both lipoplexes consisting of a...